Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that the emulsion extract of brevilin A from Centipeda minima may stimulate hair regrowth in individuals with mild to moderate vertex balding by inhibiting JAK3.

This study found that Centipeda minima and brevilin A significantly reduced oxidative stress and inflammation in human dermal fibroblasts, suggesting their potential to protect against skin aging and inflammation.

This study documented successful use of Brevilin-A, a topical treatment, in pediatric patients with alopecia areata, indicating it as a potentially safe and effective option for managing mild-moderate cases and resistant forms of the disease.

This study found that Centipeda minima extract promotes hair growth by activating Wnt/β-catenin, ERK, and JNK signaling pathways in human hair follicle dermal papilla cells.

This paper reviews current and developing treatments for severe alopecia areata but reports no new clinical findings; the authors highlight the need for standardized treatment protocols.

Humans lost body hair relatively recently in evolution.

This guideline provides recommendations for prescribing systemic testosterone to women with hypoactive sexual desire disorder, emphasizing safe dosing, monitoring, and the need for informed consent despite regulatory challenges.

In this review, researchers discussed recent insights into caspases, enzymes initially associated with cell death and inflammation, revealing their broader roles in cell proliferation, migration, and differentiation, and highlighting the importance of caspase knock-out mice for understanding their implications in diseases.

This study found that post-finasteride syndrome patients showed a tissue-specific methylation pattern of the SRD5A2 promoter in cerebrospinal fluid, potentially affecting neuroactive steroid levels and related behavioral symptoms.

This review describes the signs, symptoms, and complications of COVID-19, noting that symptoms often overlap with common and non-specific features, especially in older adults and in different stages of illness.

This review examines the potential of regulatory T cell-based therapies to transform treatment across various medical specialties by promoting immune tolerance and tissue repair, but it reports no new clinical results.

This review discusses the multifaceted roles of regulatory T cells in cutaneous wound healing and highlights potential therapeutic strategies targeting these cells to enhance wound repair in chronic and diabetic wounds, but reports no new clinical results.

This phase II trial found that BI 2536 demonstrated limited antitumor activity across five solid tumor types, with no confirmed objective responses observed.

This study found that vismodegib was effective in treating basal cell carcinoma, achieving complete remission in some patients; however, significant side effects often required careful management to prevent therapy suspension, which can lead to resistance.

In this study, brepocitinib was found to significantly reduce inflammatory biomarker CCL5 expression and improve clinical severity by week 24, while maintaining a favorable safety profile.

This study found that a high dose of LustrivaTM, containing biotin and silicon, significantly increased hair thickness and reduced facial wrinkle depth in women with thinning hair compared to a placebo, without any reported adverse events.

This compilation details various potential side effects and interactions of vitamin A, but it reports no new research findings.

VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.

In these two clinical trials, DS-2325a, a KLK5 inhibitor, was found to be generally safe and well tolerated in healthy volunteers, with mild and non-serious adverse events, suggesting its potential for further development as a treatment for Netherton Syndrome.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

This study reported that the novel topical serum REVIVV®, containing a blend of phytochemicals, significantly improved hair growth and reduced shedding in 150 participants with androgenetic alopecia after 8 weeks of use, while also being rated easy to use and prompting plans for continued use.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

In this open-label study, participants reported that the LustrivaTM BH-002 two-step system improved various aspects of hair, skin, and nail health and appearance after three months of use.

This study developed and tested Bicalutamide-loaded lipid vesicles in dissolving microarray patches for topical application, finding that they effectively deliver Bicalutamide through murine skin while maintaining a favorable safety profile, suggesting potential to improve treatments for androgenetic alopecia.

This study found that the oral JAK inhibitors ritlecitinib and brepocitinib were effective in maintaining hair regrowth in alopecia areata with continuous use, though efficacy decreased after withdrawal.

This case report found that adding lokivetmab to prednisolone treatment improved and maintained remission of pruritus in a dog with cutaneous epitheliotropic lymphoma.

This study found that 10,11-dibrominecrebanine (2Br-Cre) and Stephanine demonstrate significant anti-inflammatory and analgesic properties in various experimental models, with 2Br-Cre showing enhanced efficacy over Cre and both compounds potentially mediating their analgesic effects through opioid receptors.

This study found that VB-1, a vitexin compound, may promote hair follicle growth by enhancing Wnt/β-catenin signaling in human dermal papilla cells in vitro.

This study demonstrated that the IVL-DrugFluidic® platform is effective for mass-producing finasteride-loaded polymeric microspheres for long-acting injectables, maintaining stable drug release without an initial burst for a month.

VYC-12L effectively improves skin smoothness, reduces fine lines, and boosts hydration.